JAK inhibitors and VTE risk: how concerned should we be?

Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these...

Full description

Saved in:
Bibliographic Details
Published in:Nature reviews. Rheumatology 2021-03, Vol.17 (3), p.133-134
Main Author: Cohen, Stanley B.
Format: Article
Language:English
Subjects:
692/499
692/700/565/1436
692/700/565/2194
Arthritis, Rheumatoid
Dose-response relationship (Biochemistry)
Drug therapy
Humans
Janus kinase
Janus Kinase Inhibitors
Medicine
Medicine & Public Health
News & Views
news-and-views
Rheumatoid arthritis
Rheumatology
Risk factors
Thromboembolism
Venous Thromboembolism - chemically induced
Venous Thromboembolism - epidemiology
Venous thrombosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these concerns justified?
ISSN:1759-4790
1759-4804
DOI:10.1038/s41584-021-00575-5